Pazopanib, a tiny multi-targeted tyrosine kinase inhibitor (TKI) against VEGFR1, VEGFR2, VEGFR3, and PDGFR, has been given the green light for the treatment of metastatic BS following anthracycline-based chemotherapy or as a first line of therapy for patients who are ineligible. The gene discussed is PDGFRB; the disease is Bloom syndrome.